A new long-acting GLP-1 derivative 6-KTP ameliorates body 5 weight and lipid metabolism in DIO mice 6 7 8 Abstract 16 As a global epidemic, obesity has become the biggest challenge facing 17 global and public health. Glucagon-like peptide-1(GLP-1) has been able to 18 inhibit appetite, slow gastric emptying and reduce body weight. We 19 designed a novel long-acting GLP-1 derivative 6-KTP based on wild-type 20 GLP-1 and performed its pharmacodynamics study on obesity in DIO mice. 21 DIO mice were treated once daily with subcutaneous injections of 6-KTP 22 (1.8 mg/kg body weight), Liraglutide (0.4 mg/kg body weight) or vehicle 23 (phosphate buffered saline (PBS), pH 7.4) for 12 weeks. The results show 24 that 6-KTP decreased food intake, induced anorexia and weight loss, and 25 improved blood lipid and lipid metabolism in DIO mice.
Introduction 27
Obesity is associated with morbidity and mortality of chronic diseases 28 and other health problems, including cardiovascular disease, type II diabetes, 29 musculoskeletal disorders and certain site-specific cancers, such as 30 colorectal and breast cancer [1] . Obesity has clinical manifestations such as 
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Then the natural active GLP-1 (7-37) was ligated to obtain a long-acting 94 At the end of the administration, the mice in each group were subjected 95 with anesthesia, and blood samples were collected using cryotubes. Serum As shown in Fig 1, we confirmed that mice fed with high fat diet could 113 intake more food than that fed with normal diet. The average daily food 114 intake dose of the mice in the HFD group was 39.65 ± 1.998g, and the NC 115 group was 19.93 ± 0.9544g. The high fat diet led to an increase intake in the 116 diet of mice in the HFD group, which was beneficial to lipid accumulation 117 and promoted the construction of the obesity model. (Fig 1) intake in each group of mice showed that the long-acting GLP-1 derivative 129 6-KTP can reduce the food intake of mice. The food intake in the 6-KTP 130 group mice was significantly less than DIO group (p = 0.0197). There was 131 no significant difference between the 6-KTP group and the Liraglutide group 132 (Fig 3) . mice, the body weight was significantly reduced (Fig 4) . The body weight in 136 the 6-KTP group mice was significantly less than DIO group (p = 0.0181), 137 whereas, there was no significant difference between the 6-KTP group and 138 the Liraglutide group. 
Sample collection and biochemical parameters test

Effect of 6-KTP on blood lipid metabolism 143
To further investigate the potential changes of lipid metabolism,
144
CHOL, TG, HDL-C and LDL-C were analyzed ( Fig 5) . Compared with the 145 DIO group, the serum levels of Cholesterol (CHOL) were lower than that in 146 the NC group, the 6-KTP group and the Liraglutide group ( Fig 5A) . There 147 were significant differences between the NC group and the DIO group (p= 148 0.0008), between the 6-KTP group and the DIO group (p=0.0003), between 149 the Liraglutide group and the DIO group (p=0.0004). There was no significant 150 difference between the other groups. There was no significant difference 151 between the groups of the triglyceride (TG) levels yet ( Fig 5B) . The levels 152 of serum high density lipoprotein (HDL-C) in the NC group, 6-KTP group 153 and Liraglutide group were lower compared with the DIO group ( Fig 5C) .
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There were significant differences between the NC group and the DIO group 155 (p = 0.0006), between 6-KTP group and DIO group (p = 0.0003), between 156 Liraglutide group and DIO group (p = 0.0003). There were no significant 157 differences between other groups. The levels of low-density lipoprotein 158 (LDL-C) in the NC group, the 6-KTP group, and the Liraglutide group were 159 lower than DIO group (Fig 5D) . There were significant differences between production and adipocyte browning, and the mechanism controlling these 236 effects was located in the hypothalamic ventromedial nucleus (VMH) [15] .
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The mechanism controlling these actions is located in the hypothalamic 
